Biliary tract cancer prognostic and predictive genomics.

Area of Science:

• Oncology
• Genomics
• Cancer Biology

Background:

• Biliary tract cancer (BTC) encompasses intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (EHC), and gallbladder cancer (GBC).
• These biliary epithelium-derived tumors share histological traits and present a poor prognosis, even at early stages.
• Limited clinical trials exist due to low incidence in developed nations, hindering tailored treatment strategies.

Purpose of the Study:

• To outline genomic differences among BTC subgroups (ICC, EHC, GBC).
• To identify key milestones for developing novel targeted drugs against BTC.
• To emphasize the need for international collaboration in clinical trials.

Main Methods:

• Review of next-generation sequencing (NGS) studies.
• Analysis of genomic alterations in ICC, EHC, and GBC.
• Synthesis of current knowledge on BTC genomics.

Main Results:

• NGS studies have identified driver genes and actionable genomic alterations across BTC subtypes.
• Genomic profiling reveals distinct molecular landscapes within ICC, EHC, and GBC.
• Current standard first-line therapy (cisplatin plus gemcitabine) has limited efficacy, with few options post-progression.

Conclusions:

• Understanding genomic differences is crucial for developing targeted therapies for BTC.
• Early results for targeted drugs are promising, but require validation in larger trials.
• International collaboration is essential for adequately powered clinical trials, especially involving patients from high-incidence regions.